NCT00003875View on ClinicalTrials.gov

Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 13, 1998

Primary Completion Date

June 11, 2015

Study Completion Date

June 11, 2015

Conditions
Adult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Childhood Acute Myeloid Leukemia in RemissionRecurrent Adult Acute Myeloid LeukemiaRecurrent Childhood Acute Myeloid Leukemia
Interventions
DRUG

busulfan

Given PO or IV

DRUG

etoposide

Given IV

BIOLOGICAL

aldesleukin

Given SC

PROCEDURE

peripheral blood stem cell transplantation

Undergo autologous or syngeneic stem cell rescue

Trial Locations (1)

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT00003875 - Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter